Cargando…
A paclitaxel prodrug with bifunctional folate and albumin binding moieties for both passive and active targeted cancer therapy
Folate receptor (FR) has proven to be a valuable target for chemotherapy using folic acid (FA) conjugates. However, FA-conjugated chemotherapeutics still have low therapeutic efficacy accompanied with side effects, resulting from complications such as short circulation half-life, limited tumor deliv...
Autores principales: | Shan, Lingling, Zhuo, Xin, Zhang, Fuwu, Dai, Yunlu, Zhu, Guizhi, Yung, Bryant C., Fan, Wenpei, Zhai, Kefeng, Jacobson, Orit, Kiesewetter, Dale O., Ma, Ying, Gao, Guizhen, Chen, Xiaoyuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5858514/ https://www.ncbi.nlm.nih.gov/pubmed/29556370 http://dx.doi.org/10.7150/thno.24382 |
Ejemplares similares
-
Pro-Moieties of Antimicrobial Peptide Prodrugs
por: Forde, Eanna, et al.
Publicado: (2015) -
Prodrug Strategies for Paclitaxel
por: Meng, Ziyuan, et al.
Publicado: (2016) -
Folate-PEG Conjugates of a Far-Red Light-Activatable
Paclitaxel Prodrug to Improve Selectivity toward Folate Receptor-Positive
Cancer Cells
por: Thapa, Pritam, et al.
Publicado: (2017) -
Bioresponsive albumin-conjugated paclitaxel prodrugs for cancer therapy
por: Yang, Jincheng, et al.
Publicado: (2018) -
Fluorine-18 Radiochemistry, Labeling Strategies and
Synthetic Routes
por: Jacobson, Orit, et al.
Publicado: (2014)